20:08 , Mar 1, 2019 |  BC Week In Review  |  Company News

Sarepta acquires Myonexus, reports LGMD trial results

Sarepta Therapeutics Inc. (NASDAQ:SRPT) exercised its option to acquire Myonexus Therapeutics Inc. (New Albany, Ohio), giving it a pipeline of five gene therapy candidates to treat forms of limb-girdle muscular dystrophy (LGMD). Sarepta also revealed...
15:47 , Feb 27, 2019 |  BC Extra  |  Company News

On strength of first LGMD data, Sarepta exercises option to buy Myonexus

Sarepta Therapeutics Inc. (NASDAQ:SRPT) exercised its option to acquire Myonexus Therapeutics Inc. (New Albany, Ohio), giving it a pipeline of five gene therapy candidates to treat forms of limb-girdle muscular dystrophy (LGMD). Sarepta also revealed...
19:00 , Jan 4, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: December 2017

New Therapeutic Targets and Biomarkers: December 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during December 2017. Therapeutic targets are defined as any protein, gene or other...